Haemonetics Retires 2026 Convertible Notes, Simplifies Capital Structure
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Haemonetics ( (HAE) ) has shared an announcement.
On March 2, 2026, Haemonetics Corporation fully repaid at maturity its outstanding 0.00% Convertible Senior Notes due 2026, paying $300 million in cash equal to the principal amount. The company funded the repayment with cash on hand and borrowings under its revolving credit facility, and no noteholders exercised conversion rights before the maturity date.
With the maturity of the notes, the related capped call transactions expired in line with their terms, simplifying the company’s capital structure. The move removes this convertible debt from Haemonetics’ balance sheet, which may reduce potential future equity dilution while modestly increasing reliance on its revolving credit facility for liquidity.
The most recent analyst rating on (HAE) stock is a Buy with a $88.00 price target. To see the full list of analyst forecasts on Haemonetics stock, see the HAE Stock Forecast page.
Spark’s Take on HAE Stock
According to Spark, TipRanks’ AI Analyst, HAE is a Neutral.
The score is held back most by weak technicals (sharp downtrend and bearish momentum). Fundamentals are mixed: strong cash generation and profitability are offset by a steep TTM revenue decline and higher leverage. Valuation is reasonable at ~16x earnings, and the latest earnings call was supportive due to raised EPS/FCF guidance despite acknowledged segment headwinds.
To see Spark’s full report on HAE stock, click here.
More about Haemonetics
Haemonetics Corporation is a medical technology company that provides blood management solutions, including devices, software and services used in blood and plasma collection, transfusion and related hospital procedures. The company focuses on improving blood safety and efficiency for hospitals, blood centers and plasma collection facilities worldwide.
Average Trading Volume: 856,788
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.97B
For detailed information about HAE stock, go to TipRanks’ Stock Analysis page.
